Amytrx Therapeutics, a US-based biopharmaceutical company specialising in the development of novel therapies for dermatology and inflammation, announced on Tuesday that it has added Dr Michael Howell and Dr Satish Joshi as its new directors.
Dr Howell has over 20 years of experience in allergy, autoimmunity, dermatology, inflammatory and oncology diseases. He has played an important role in various clinical trials and has published extensively on topics regarding dermatological and immunological conditions.
Dr Joshi has more than 25 years of experience in the peptide API business. He has been at the forefront of peptide product development throughout his career.
Dr Matthew A. Gonda, Amytrx Therapeutics CEO, said: "Amytrx Therapeutics is excited to welcome Dr. Howell and Dr. Joshi to our board of directors. Their exceptional scientific and business backgrounds align perfectly with our mission to bring transformative treatments to patients in need. Their contributions will be invaluable as we continue to advance our lead candidate, AMTX-100, and work towards its successful commercialisation."
Incyte and Syndax receive US FDA approval for Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vials
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
PacBio and Intus Bio launch GutID, first at-home microbiome test powered by HiFi sequencing
Xentria announces operational expansion of multiple clinical trials in 2025
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment